OMER - Omeros stock plunges 48% on failed Phase 3 study for narsoplimab
2023-10-16 10:07:28 ET
More on Omeros
- Omeros: Where Medical Hopes Tangle With Fiscal Ropes
- Omeros: Betting Big On Narsoplimab, We Are Still A Buyer
- Omeros Corporation (OMER) Q2 2023 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Omeros
- Historical earnings data for Omeros
For further details see:
Omeros stock plunges 48% on failed Phase 3 study for narsoplimab